About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00500318

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in ...

Lead sponsor: AstraZeneca•42 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•A diagnosis of stable moderate to severe COPD (GOLD 2006); post-levalbuterol FEV1 \>=30% and \< 80% predicted and FEV1/FVC\<70% predicted
•Current or former cigarette smoker
•Functional Residual Capacity (FRC) measured by body plethysmography \>= 120% of predicted value
•Baseline Dyspnea Index (BDI) focal score ≤ 7 at Visit 4

Exclusion Criteria

•History of presence of asthma, allergic rhinitis, or atopy
•Hospitalization for acute COPD exacerbation in the 3 months prior to study entry
•Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry
•Clinically significant respiratory conditions other than COPD
•Chronic use of oxygen therapy \>= 15 hours a day

Related studies

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

NCT06712563 · Pulmonary Disease, Chronic Obstructive

Additional Effects of Box Breathing Technique With Short Term Pulmonary Rehabilitation on Dyspnea and Functional Capacity in Patients With Chronic Obstructive Pulmonary Disease

NCT07518472 · Pulmonary Disease, Chronic Obstructive (COPD)

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

NCT06831994 · Asthma Bronchiale, Breast Neoplasms, and more

Investigation of Walking Training With Different Slope Types in COPD Patients

NCT06283004 · Pulmonary Disease, Chronic Obstructive

Reducing the Number of Hospital Admissions With Multiple Nursing Interventions in COPD Patients Using Oxygen Concentrators at Home

NCT05730088 · Pulmonary Disease, Chronic Obstructive

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 6, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment181

Start dateJul 2007

Last updatedJan 6, 2017

Condition

Pulmonary Disease, Chronic Obstructive

Locations shown

Forest Investigative Site 2088

Jasper, Alabama

Forest Investigative Site 0909

Phoenix, Arizona

Forest Investigative Site 0957

Long Beach, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2017Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions